Cydy. From the same article. It is important to n

Cydy. From the same article.
It is important to note that Leronlimab has no strong safety signals recognized in several disease continuums, counting HIV, COVID-19, and oncology. At this point in time, I can’t find another drug that has such broad applications with the same level of safety.

Demonstrating Potential

These latest developments show that all of Leronlimab’s potential indications are still in play, with some of them moving closer to approval. Not only is this important for those specific programs, but it also validates Leronlimab’s potential to be operative in the other potential indications. It is possible that Leronlimab could be a “jack of all trades” to be used in, oncology, metabolic diseases, neurodegenerative diseases, and autoimmune diseases. These divisions of medicine have immense market opportunities that have plenty of room for novel therapeutics, especially ones that have amazing safety profiles such as Leronlimab. Keep in mind, that most of these diseases are chronic, so a patient could be on Leronlimab for the rest of their life or until there is another option on the market. In addition, patients with these diseases typically have comorbidity and possibly have one or more of Leronlimab’s target indications. Hopefully, Leronlimab will be eventually seen as the physician’s version of “duct tape” where it is essential to have in the toolbox and is believed to be able to fix everything.